- $6.50m
- -$10.90m
- 13
- 50
- 46
- 29
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.36 | ||
| Price to Tang. Book | 0.36 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -164.36% | ||
| Return on Equity | -138.06% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.57 | 3.67 | 1.56 | 1 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aptinyx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. The Company focuses on targeting and modulating N-methyl-D-aspartate receptors, (NMDArs), which are vital to the normal and effective function of the brain and nervous system. The Company's NYX-783 is in Phase 1 clinical development for the treatment of opioid use disorder (OUD), and in preclinical development for the treatment of alcohol use disorder. NYX-783 modulates NMDA receptors to increase glutamatergic activity in key regions and may act to enhance extinction learning and alleviate the emotional symptoms of opioid withdrawal. The Company's NMDAr modulator discovery platform builds on NMDAr biology. The platform has the potential to develop into a broad pipeline and product portfolio across an array of disorders of the brain and nervous system.
Directors
- Norbert Riedel CHM (63)
- Andrew Kidd PRE (45)
- Ashish Khanna CFO (45)
- Patrick Enright LED (59)
- Henry Gosebruch IND (48)
- Elisha Gould IND (64)
- Robert Hombach IND (55)
- Adam Koppel IND (51)
- Joan Miller IND (62)
- Gilmore O Neill IND (56)
- Rachel Sherman IND (63)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- June 24th, 2015
- Public Since
- June 21st, 2018
- No. of Shareholders
- 47
- No. of Employees
- 12
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 67,715,718
- Address
- 1801 Maple Ave Ste 4300, EVANSTON, 60201-3149
- Web
- https://www.aptinyx.com/
- Phone
- +1 8478710377
- Auditors
- Deloitte & Touche LLP
Upcoming Events for APTX
Similar to APTX
Acacia Diversified Holdings
Pink Sheets on Nasdaq
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 18:02 UTC, shares in Aptinyx are trading at $0.10. This share price information is delayed by 15 minutes.
Shares in Aptinyx last closed at $0.10 and the price had moved by -68.01% over the past 365 days. In terms of relative price strength the Aptinyx share price has underperformed the S&P500 Index by -73.23% over the past year.
The overall consensus recommendation for Aptinyx is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Aptinyx does not currently pay a dividend.
Aptinyx does not currently pay a dividend.
Aptinyx does not currently pay a dividend.
To buy shares in Aptinyx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.10, shares in Aptinyx had a market capitalisation of $6.50m.
Here are the trading details for Aptinyx:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: APTX
Based on an overall assessment of its quality, value and momentum Aptinyx is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Aptinyx is $0.50. That is 420.83% above the last closing price of $0.10.
Analysts covering Aptinyx currently have a consensus Earnings Per Share (EPS) forecast of -$0.47 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aptinyx. Over the past six months, its share price has outperformed the S&P500 Index by +21.94%.
As of the last closing price of $0.10, shares in Aptinyx were trading +18.13% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Aptinyx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Aptinyx's management team is headed by:
- Norbert Riedel - CHM
- Andrew Kidd - PRE
- Ashish Khanna - CFO
- Patrick Enright - LED
- Henry Gosebruch - IND
- Elisha Gould - IND
- Robert Hombach - IND
- Adam Koppel - IND
- Joan Miller - IND
- Gilmore O Neill - IND
- Rachel Sherman - IND